Drugs / 68Ga-NYM005
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06389682 | Jun 2024 → Jan 2025 | clear cell renal carcinoma | Norroy Bioscience Co., LTD | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-NYM005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06389682 ↗ |
| Modality | Diagnostic / imaging agent | “68Ga-NYM005 is a CAIX-targeting small-molecular radiotracer for PET/CT imaging of clear cell renal cell carcinoma” NCT06389682 ↗ |
| Route | Intravenous | “the dose will be administered via an intravenous injection” NCT06389682 ↗ |